COVID AND THE VACCINE - TRUTH, LIES, AND MISCONCEPTIONS REVEALED, page-67604

Nope I'll stick with the pills thanks


The study conducted in 399 participants met its primary efficacy endpoint with a reduction of 72% of COVID-19 infection in the group treated with daily oral administration of ivermectin compared to the placebo group

Ivermectin administered for 28 days demonstrated acceptable safety and tolerability without any unexpected safety signals

The SAIVE study was conducted to support mdc-TTG program, whose objective is to provide prevention of Covid-19 infection for weeks or months with a single injection of a long-acting formulation of ivermectin based on MedinCell’s proprietary technology, BEPO®

https://www.medincell.com/wp-content/uploads/2023/01/PR-results-TTG-VF-EN.pdf